Cao X, Zhang M, Guo R, Zhang X, Sun R, Xiao X
Chin Med J (Engl). 2024; 138(1):111-113.
PMID: 39658252
PMC: 11717506.
DOI: 10.1097/CM9.0000000000003353.
Yang Y, Peng H, Wang J, Li F
Exp Hematol Oncol. 2024; 13(1):110.
PMID: 39521987
PMC: 11549815.
DOI: 10.1186/s40164-024-00573-9.
Ferreri C, Bhutani M
Front Oncol. 2024; 14:1396490.
PMID: 38835382
PMC: 11148294.
DOI: 10.3389/fonc.2024.1396490.
Ma S, Wang Y, Qi K, Lu W, Qi Y, Cao J
Cancer Immunol Immunother. 2024; 73(6):104.
PMID: 38630258
PMC: 11024067.
DOI: 10.1007/s00262-024-03661-1.
Liang E, Sidana S
Hematology Am Soc Hematol Educ Program. 2023; 2023(1):348-356.
PMID: 38066898
PMC: 10727020.
DOI: 10.1182/hematology.2023000435.
Recognizing, defining, and managing CAR-T hematologic toxicities.
Rejeski K, Subklewe M, Locke F
Hematology Am Soc Hematol Educ Program. 2023; 2023(1):198-208.
PMID: 38066881
PMC: 10727074.
DOI: 10.1182/hematology.2023000472.
Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review.
Khanam R, Faiman B, Batool S, Najmuddin M, Usman R, Kuriakose K
J Clin Med. 2023; 12(17).
PMID: 37685606
PMC: 10487885.
DOI: 10.3390/jcm12175539.
An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA.
Rejeski K, Greco R, Onida F, Sanchez-Ortega I, Bonini C, Sureda A
Hemasphere. 2023; 7(5):e889.
PMID: 37125259
PMC: 10145722.
DOI: 10.1097/HS9.0000000000000889.
Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis.
Reinhardt B, Lee P, Sasine J
Cells. 2023; 12(4).
PMID: 36831198
PMC: 9954220.
DOI: 10.3390/cells12040531.
How I treat cytopenias after CAR T-cell therapy.
Jain T, Olson T, Locke F
Blood. 2023; 141(20):2460-2469.
PMID: 36800563
PMC: 10646792.
DOI: 10.1182/blood.2022017415.
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma.
Miller K, Johnson P, Abramson J, Soumerai J, Yee A, Branagan A
Blood Cancer J. 2022; 12(10):146.
PMID: 36316312
PMC: 9622902.
DOI: 10.1038/s41408-022-00741-2.
CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias.
Taneja A, Jain T
EJHaem. 2022; 3(Suppl 1):32-38.
PMID: 35844301
PMC: 9175816.
DOI: 10.1002/jha2.350.
Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.
Wudhikarn K, Perales M
Bone Marrow Transplant. 2022; 57(10):1477-1488.
PMID: 35840746
PMC: 9285870.
DOI: 10.1038/s41409-022-01756-w.
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski K, Perez A, Iacoboni G, Penack O, Bucklein V, Jentzsch L
J Immunother Cancer. 2022; 10(5).
PMID: 35580927
PMC: 9114843.
DOI: 10.1136/jitc-2021-004475.
